Decoy Therapeutics Inc.
DCOY· Nasdaq
DCOYDecoy Therapeutics Inc.
Filed Mar 18, 2021 · 10-K · 77 days after period end · 0001615219-21-000026
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $1.48M | $1.04M | $163.07K | $282.83K |
| Net Income | -$1.77M | -$1.88M | -$2.01M | -$8.03M |
| EPS Diluted | — | — | -$0.11 | -$0.46 |
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Mar 18, 2021 · 77 d after period end
